LRMR Larimar Therapeutics, Inc.
$3.92▲ +1.82%
Healthcare
Other
After hours
$3.94▲ +0.51%
Sep 11, 7:38 PM ET
Volume 2.13M
Avg Volume (10D) 761.5K
Key Metrics & Fundamentals
Market Cap
$407.22M
P/E Ratio
–
Div Yield
–%
52W Range
2.72 - 6.42
% vs 50 MA
-0.82%
% vs 200 MA
-0.54%
RSI-14
47.8
MACD Histogram
-0.0300
Beta (1Y vs SPY)
1.74
Free Cash Flow
-$44.16M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$34.29M
COGS
–
Operating Exp
$34.35M
Operating Income
-$34.35M
EBIT
-$34.35M
Pretax Income
-$32.78M
Net Income
-$32.78M
EPS (Diluted)
-0.30
Price & Volume History
Loading chart…
Recent News
Century Therapeutics Appoints Joseph Truitt to Board of Directors
GlobeNewswire · Sep 9, 2026 8:05 PM
Larimar: Q2 Earnings Snapshot
Associated Press · Aug 4, 2026 11:09 AM
Larimar Therapeutics Reports Second Quarter 2026 Financial and Business Update
GlobeNewswire · Aug 4, 2026 11:00 AM
Larimar Therapeutics (LRMR) Submits Initial Module of BLA For Nomlabofusp Therapy
Insider Monkey · Jul 15, 2026 3:43 PM
LRMR Stock Edges Up After Hours After Director Purchases Shares Worth About $167,000
Stocktwits · Jul 8, 2026 10:44 PM
Here’s What Citi Thinks About Larimar Therapeutics (LRMR)
Insider Monkey · Jul 3, 2026 1:13 PM
LRMR Shares Hold Steady As Wall Street Optimism Offsets Drug Safety Concerns
Stocktwits · Jul 2, 2026 8:32 PM
Larimar Therapeutics Shares Drop Following Clinical Update and Regulatory Filing (LRMR)
InvestorsHub · Jun 29, 2026 2:00 PM
Larimar's Rare Disease Push Just Hit A Key Inflection Point — What Investors Need To Know
Stocktwits · Jun 29, 2026 1:02 PM
Larimar Therapeutics Files First Module of BLA With US FDA for Nomlabofusp
MT Newswires · Jun 29, 2026 12:26 PM
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
See LRMR's money flow as a full page
Social Sentiment
No Reddit posts found for LRMR.
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.